PMID- 30343488
OWN - NLM
STAT- MEDLINE
DCOM- 20191011
LR  - 20200309
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 125
IP  - 1
DP  - 2019 Jan 1
TI  - Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER 
      patterns of care analysis.
PG  - 135-143
LID - 10.1002/cncr.31738 [doi]
AB  - BACKGROUND: Laboratory testing and treatments for chronic lymphocytic leukemia 
      (CLL) have changed dramatically within the last decade. The authors evaluated 
      changes in patterns of real-world testing and treatment over time by comparing 2 
      population-based cohorts. METHODS: The National Cancer Institute-sponsored 
      Patterns of Care study was conducted among patients with CLL who were sampled 
      from 14 Surveillance, Epidemiology, and End Results (SEER) program registries. 
      Demographics, testing, and treatment data were abstracted from medical records 
      within 24 months of diagnosis. RESULTS: A total of 1008 patients diagnosed in 
      2008 and 1367 patients diagnosed in 2014 were included. There was a significant 
      increase in fluorescence in situ hybridization (FISH) testing, immunoglobulin 
      heavy-chain variable region gene (IgV(H) ) mutation analyses, and lymph node 
      biopsies between 2008 and 2014. FISH testing was performed in the majority of, 
      but not all, treated patients (53% in 2008, which increased to 62% in 2014). Some 
      differences in the receipt of FISH testing by age and insurance status were 
      observed over time (older patients and Medicare patients without private 
      insurance were less likely to be tested in 2014). There were contrasting testing 
      patterns noted by practice type and year, with nonteaching hospitals more likely 
      to perform bone marrow biopsies in 2008, and teaching hospitals more likely to 
      perform FISH and IgV(H) testing in 2014. There also were differences in 
      treatments over time, with the use of bendamustine and rituximab being more 
      common in 2014, at the expense of fludarabine, cyclophosphamide, and rituximab. 
      CONCLUSIONS: There have been rapidly changing practices in the testing and 
      treatment patterns of patients with CLL within the last decade.
CI  - (c) 2018 American Cancer Society.
FAU - Seymour, Erlene K
AU  - Seymour EK
AD  - Division of Hematology/Oncology, Department of Oncology, Karmanos Cancer 
      Institute, Wayne State University, Detroit, Michigan.
FAU - Ruterbusch, Julie J
AU  - Ruterbusch JJ
AD  - Division of Hematology/Oncology, Department of Oncology, Karmanos Cancer 
      Institute, Wayne State University, Detroit, Michigan.
FAU - Beebe-Dimmer, Jennifer L
AU  - Beebe-Dimmer JL
AD  - Division of Hematology/Oncology, Department of Oncology, Karmanos Cancer 
      Institute, Wayne State University, Detroit, Michigan.
FAU - Schiffer, Charles A
AU  - Schiffer CA
AD  - Division of Hematology/Oncology, Department of Oncology, Karmanos Cancer 
      Institute, Wayne State University, Detroit, Michigan.
LA  - eng
GR  - HHSN261201300011C/RC/CCR NIH HHS/United States
GR  - HHSN261201300011I/CA/NCI NIH HHS/United States
GR  - P30 CA022453/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20181021
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bendamustine Hydrochloride/therapeutic use
MH  - DNA Mutational Analysis/statistics & numerical data
MH  - Diagnostic Techniques and Procedures/classification/*trends
MH  - Female
MH  - Humans
MH  - Immunoglobulin Variable Region/genetics
MH  - In Situ Hybridization, Fluorescence/statistics & numerical data
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/*drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Rituximab/therapeutic use
MH  - SEER Program
MH  - Sentinel Lymph Node Biopsy/statistics & numerical data
PMC - PMC6309467
MID - NIHMS985338
OTO - NOTNLM
OT  - Epidemiology
OT  - Surveillance
OT  - and End Results (SEER)
OT  - chronic lymphocytic leukemia (CLL)
OT  - patterns of care
OT  - testing
OT  - treatments
COIS- All authors have no conflicts of interest to disclose.
EDAT- 2018/10/22 06:00
MHDA- 2019/10/12 06:00
PMCR- 2020/01/01
CRDT- 2018/10/22 06:00
PHST- 2018/06/26 00:00 [received]
PHST- 2018/07/24 00:00 [revised]
PHST- 2018/08/07 00:00 [accepted]
PHST- 2018/10/22 06:00 [pubmed]
PHST- 2019/10/12 06:00 [medline]
PHST- 2018/10/22 06:00 [entrez]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.1002/cncr.31738 [doi]
PST - ppublish
SO  - Cancer. 2019 Jan 1;125(1):135-143. doi: 10.1002/cncr.31738. Epub 2018 Oct 21.